FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Friday

 

Clinical Studies of Cannabinoid Capsules for MS Expected Later This Year






Multiple sclerosis (MS) is a disease characterized by the destruction of insulating covers on nerve cells by the immune system. The most common form for the disease, relapsing-remitting MS, is characterized by clearly defined attacks of decreasing neurologic function (relapses) followed by partial or complete recovery periods (remissions). Research into novel therapy approaches continues to investigate safer, more effective alternatives to the currently approved MS therapies. The use of cannabinoid-based therapies in particular appear to show promise for controlling relapses in those with the disease.

MMJ PhytoTech, a drug development company working on cannabinoid-based therapies, plans to initiate clinical studies of new capsule formulations derived from cannabis for the treatment of MS later this year. Their phase 1, safety-oriented clinical studies have been approved by various ethics committees and public health organizations. The company has been actively investigating a new capsule that offers many advantages over smokeable cannabinoid formulations, as oral administration is much more controllable and user-friendly. Furthermore, the company is confident that their capsules can withstand room temperature storage for extended periods of time. In this way, the need for refrigeration is eliminated resulting in lower shipping and storage costs.

In the end, the company believes that these advantages will give rise to a low cost cannabinoid alternative with potentially high patient compliance. The safety of these Tetrahydrocannabinol and Cannabidiol capsules will be tested in a small group of volunteers to test for adverse effects. They are expected to have a low frequency of side effects and, if proven as such, the company plans to conduct Phase 2 clinical studies to investigate the efficacy and optimal dosing schedule for MS patients. After the studies are complete, the company will need to develop Phase 3 clinical trials to assess efficacy, effectiveness and safety of the drug in around 1,000 MS patients.

The availability of clinical trials is important for medicine as it helps in the development of the treatments of tomorrow. Patients participating in clinical trials help researchers get closer to discovering new and effective therapies and/or cures for the disease. Moreover, clinical trials also give patients access to experimental therapies that are otherwise unavailable and that might offer enhanced treatment benefits than currently approved therapies for MS.

The main goal of this research is to enhance the availability of highly effective cannabinoid extracts to the general public while lowering costs and developing and easier and more stable formulation, which could tremendously impact patient outcomes for those with Multiple Sclerosis.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length 
Click here to read original article

Labels:



Go to Newer News Go to Older News